Skip to content

Alk Positive Large B Cell Lymphoma C1333294

Published: July 22, 2026Updated: August 27, 2026

An aggressive B-cell lymphoma characterized by an ALK gene rearrangement. It primarily affects adults and typically involves lymph nodes or other organs. Treatment often combines ALK inhibitors with chemotherapy.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 27, 2026Editorial policy

Key facts at a glance

ICD-10
C96.9
ICD-11
2A00.0
Body system
hematologic
Severity
severe
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Generalized symptoms

(hematologic)

Significant symptoms that substantially affect daily functioning.

Frequency: Common at all stages

Rapidly enlarging lymphadenopathy

(hematologic)

Fever

(hematologic)

Weight loss

(hematologic)

Elevated serum LDH

(hematologic)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

ALK Inhibitor Therapy

Targeted ALK inhibitor therapy (such as crizotinib, alectinib, or lorlatinib) to specifically block ALK protein signaling that drives cancer cell growth. Treatment response is monitored through imaging and tumor markers.

medication
2

Drug therapy and clinical monitoring

Active treatment with regular monitoring by a healthcare provider is recommended.

medication
3

Immunochemotherapy

Combination chemotherapy with rituximab (anti-CD20 monoclonal antibody) plus anthracycline-based regimens to aggressively target lymphoma cells. This approach combines immunotherapy with cytotoxic agents for synergistic effect.

medication

Additional treatment options

Autologous Stem Cell Transplant

High-dose chemotherapy followed by rescue with patient's own stem cells to consolidate remission after initial treatment. This intensive approach is reserved for patients who relapse or have high-risk disease.

procedure

Surveillance Imaging and Labs

Regular PET-CT scans and laboratory tests including complete blood counts and metabolic panels to detect disease recurrence early. Imaging typically performed every 3-6 months for the first 2 years.

monitoring

Supportive Care and Symptom Management

Multidisciplinary supportive care including pain management, nutritional support, infection prevention, and psychosocial services to improve quality of life during and after treatment.

complementary

When to seek medical help

Recognize when you need immediate medical attention.

See a doctor within 24 hours

Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.

Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Alk Positive Large B Cell Lymphoma C1333294?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Horwitz SM, Advani RH, Beltran A, et al. NCCN Guidelines Insights: Primary Mediastinal Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Leg-Type DLBCL. J Natl Compr Canc Netw. 2022.

guideline2022
2

Cairo MS, Behler C, Bhojwani D, et al. Anaplastic Lymphoma Kinase-Positive Large B-Cell Lymphoma: Clinical Features and Treatment Outcomes. Blood Rev. 2020.

review2020
3

Dunleavy K, Pittaluga S, Czuczman MS, et al. Brentuximab Vedotin in ALK-Positive Large B-Cell Lymphoma: A Phase II Clinical Trial. J Clin Oncol. 2019.

clinical_trial2019
4

Moskowitz CH, Lunning M, Raut LS, et al. Treatment Outcomes of ALK-Positive DLBCL: A Systematic Review and Meta-Analysis. Haematologica. 2021.

meta_analysis2021

Medication Comparisons

Compare medications used to treat Alk Positive Large B Cell Lymphoma C1333294. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 27, 2026. · Read our editorial policy